Core Viewpoint - The company has successfully passed the veterinary drug GMP acceptance and obtained the Veterinary Drug GMP Certificate and Production License, indicating an expansion in its production capabilities and product range in the vaccine and biological products sector [1][2]. Group 1: GMP Certificate and Production License - The company’s Lanzhou branch has received the Veterinary Drug GMP Certificate, which covers the production of various vaccines including inactivated vaccines for foot-and-mouth disease and live vaccines [1]. - The effective period for both the GMP Certificate and the Production License is from January 14, 2026, to January 13, 2031 [1]. Group 2: Production Capabilities and Product Development - The newly approved production lines for cell suspension culture live vaccines and bacterial live vaccines will be utilized for producing vaccines such as the live vaccine for pseudorabies in pigs and the live vaccine for piglet paratyphoid [1]. - The company is in the process of applying for the veterinary product approval numbers for the pseudorabies live vaccine and the piglet paratyphoid live vaccine to expedite their market launch [1]. - The acquisition of the GMP Certificate and Production License signifies that the production lines meet the regulatory requirements, enhancing the company’s core competitiveness and profitability by diversifying its product offerings [2].